The GPR119 agonists MBX-2982 and PSN821 reduce fasting and post-prandial glucose levels in healthy subjects with fasting hyperglycemia or impaired glucose tolerance [44], [45] and in subjects with T2D [46], but these drugs may have off-target effects on gastric emptying. Here, GPR119 is linked to Hyperglycemia.